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Abstract
Background: In Caucasian populations, the tumor cells of Epstein Barr virus (EBV)-positive classical Hodgkin Lymphomas
(cHL) patients more frequently express HLA class I and HLA class II molecules compared to EBV-negative cHL patients. HLA
expression (in relation to EBV) in Asian cHL patients has not been previously investigated.
Methodology/Principal Findings: We randomly selected 145 cHL patients with formalin-fixed, paraffin embedded tissue
blocks available from 5 hospitals from the Northern part of China. Hematoxylin & Eosin-stained slides were used to reclassify
the histological subtypes according to the WHO classification. EBV status was determined by visualization of EBERs in tumor
cells using in situ hybridization. Membranous expression of HLA molecules was detected by immunohistochemistry using
antibodies HC-10 (class I heavy chain) and anti-ß2-microglobulin for HLA class I, and CR3/43 for HLA class II. EBV+ tumor cells
were observed in 40% (58/145) of the cHL patients. As expected, the percentage of EBV+ cases was much higher in the
mixed cellularity subtype (71%) than in the nodular sclerosis subtype (16%) (p,0.001). Expression of HLA class I was
observed in 79% of the EBV+ cHL cases and in 30% of the EBV- cases (p,0.001). For HLA class II, 52% of EBV+ cHL cases
were positive, compared to 43% in EBV- cases (p=0.28).
Conclusions: The results in the Northern China population were similar to those in the Caucasian population for HLA class I,
but not for HLA class II.
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Introduction
Classical Hodgkin lymphoma (cHL) is a malignant neoplasm of
the immune system, characterized by a minority of B cell derived
tumor cells, named Hodgkin Reed-Sternberg cells (HRS cells) and
numerous reactive cells consisting of lymphocytes, histiocytes,
eosinophils, and plasma cells. The HRS cells are large, sometimes
bi- or multinucleated cells with prominent nucleoli and a
characteristic CD20 negative to weakly positive, CD30+ and
CD15+/2 immunophenotype [1]. However, the presence of HRS
cells in an abundant inflammatory infiltrate indicates that anti-
tumor immune responses apparently are insufficient for the
eradication of HRS cells. It has been shown that the tumor cells
of cHL employ several mechanisms to escape from immune
responses, even more so in Epstein Barr virus (EBV) associated
cases [2–4]. EBV has been acknowledged as the major infectious
agent causing cHL, although the proportion of EBV associated
cHL varies from 20% to nearly 100% in different populations
[3,5]. In addition, the proportion of EBV+ cases is also age-
dependent with a first high incidence peak in children and a
second peak in adults around age 60 [3,5]. EBV-infected HRS
cells consistently express a limited set of proteins, consisting of
latent membrane protein 1 (LMP1), latent membrane protein 2
(LMP2) and EBV nuclear antigen 1 (EBNA1) [5]. Antigenic
peptides derived from these three proteins can be processed and
presented by the human leukocyte antigen (HLA) class I and class
II pathways, the efficiency of which largely depends on the peptide
binding affinity of the highly polymorphic HLA alleles [6,7][8,9].
Cytotoxic T lymphocytes (CTLs) are known to be the primary
effector cells to eradicate EBV-infected B cells that present LMP1
and LMP2 antigenic peptides in the context of appropriate HLA
class I molecules [6,7]. In addition, there’s in vitro evidence that
EBV infection and the related malignant transformation are
controlled by CD4+ T cells, depending on HLA class II restricted
antigen presentation [10]. In other words, both HLA class I-
restricted CTL responses and HLA class II-restricted CD4+ T-cell
responses are essential for a successful anti-tumor immune defense.
Therefore, downregulation of HLA class I and HLA class II
antigens might be implicated in the pathogenesis of cHL by
allowing tumor cells to escape host immunosurveillance.
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HLA expression and cHL in the Western population [11–16],
but nothing is known for the Asian population. Since HLA types
are known to widely differ between Caucasians and Asians, we
set out to investigate the expression of HLA molecules in
Chinese cHL cases for drawing comparison between the two
populations. We studied HLA class I as well as HLA class II
expression in relation to EBV status in a population from the
Northern part of China.
Materials and Methods
Patient material
Formalin-fixed paraffin-embedded tissue blocks of lymph node
biopsies from 145 cHL patients were obtained from 5 hospitals in
northern China (Dept. of Pathology, Health Science Center, Peking
University; Dept. of Pathology, First Hospital of Jilin University;
Dept. of Pathology, Shougang Hospital, Peking University; Dept. of
Pathology, Beijing Air Army General Hospital; Zhanye Regional
Hospital, Gansu Province). The biopsies were stained with
hematoxylin & eosin (H&E) and histopathological subtyping was
performed according to the WHO classification.
In situ hybridization
Detection of EBV in tumor cells was performed by in situ
hybridization (ISH) on paraffin sections with a fluorescein-
conjugated PNA probe specific for the EBV-encoded EBER
RNAs (DAKO, Glostrup, Denmark). A known EBV+ tissue
section was used as a positive control.
Immunohistochemical staining
4-mm thick paraffin sections were deparaffinized by xylene and
rehydrated through a graded ethanol series into water. Microwave
antigen retrieval was performed with Tris-EDTA solution (10mM
Tris Base, 1mM EDTA Solution, PH 9.0) and endogenous
peroxidase activity was blocked in 3% H2O2. The expression of
HLA class I was detected using monoclonal antibody HC-10 at a
dilution of 1:200 (kindly provided by Prof. dr. J. Neefjes, the
Netherlands Cancer Institute, Amsterdam), which recognizes HLA
B and C molecules, as well as a few HLA-A molecules [17]. In
addition, the polyclonal rabbit anti human ß2-microglobulin
(DAKO) at a dilution of 1:200 was used as an additional marker to
detect HLA class I. For detection of HLA class II, we used the
CR3/43 monoclonal antibody (DAKO) that binds to a specific
monomorphic epitope in the ß chain of HLA-DP, HLA-DQ and
HLA-DR. All antibodies were detected using a standard Avidin
Biotin Complex (ABC) immunoperoxidase method. Diaminoben-
zidine was used as the chromogen and hematoxylin was used for
counterstaining.
Evaluation of HLA class I and class II staining
HLA class I heavy chain (HC-10) staining was scored
simultaneously with ß2-microglobulin staining. The same scoring
rules were used for HLA class II. The surrounding inflammatory
cells were used as an internal positive control and also as a
reference for assessing the intensity of HLA expression by HRS
cells. A strong membranous staining on at least 50% of the tumor
cells was identified as positive. In case the staining intensity on the
tumor cells was similar to the intensity on the surrounding reactive
cells, membranes in between adjacent tumor cells were evaluated.
Statistical analysis
HLA expression was determined in relation to EBV status.
Differences between EBV+ and EBV-neg groups in relation to
HLA expression as well as several clinicopathologic variables were
assessed by Chi square test, Fisher’s exact test or Mann Whitney U
test. The correlation between HLA class I and class II expression
was evaluated with Chi square test. In addition, multivariate
analysis using logistic regression was performed to adjust for
confounders. The data were analyzed with SPSS for windows,
version 16.0. A p-value ,0.05 was considered significant.
Results
Clinicopathologic features
145 patients diagnosed with cHL were subdivided into
histological subtypes according to the WHO classification.
Subtype could not be unequivocally determined in 18% (n=26),
usually because there was not enough tissue to properly evaluate
the background architecture. These patients were classified as
cHL, not otherwise specified (NOS). In the remaining patients the
nodular sclerosis (NS) subtype was the most common one,
accounting for 63% (n=75) of patients, followed by mixed
cellularity (MC) with 35% (n=42) of patients. The lymphocyte
rich (LR) subtype was rare (n=2) and the lymphocyte depleted
subtype was absent. The median age of the patients at the time of
diagnosis was 28 years, ranging from 4 to 74 years. There was a
clear male predominance with a male to female ratio of 2:1.
EBV status and clinicopathologic variables
EBERs in HRS cells were demonstrated in 40% of the patients
(n=58). In these patients, all tumor cells showed consistent
nuclear labeling (see figure 1). A low number of positive small
bystander cells were observed in some cases.
Subtype and sex demonstrated statistically significant differences
between EBV+ and EBV-neg cases. As expected, the MC subtype
showed the highest percentage of EBV+ cases (30 of 42 cases
[71%]). In addition, males more frequently had EBV+ cHL than
females (48% compared to 24%). In terms of patients’ age, no
significant difference was found between EBV-associated and non-
EBV-associated cHL (Table 1).
HLA class I and HLA class II expression
Expression of HLA class I heavy chains was consistent with that
of ß2-microglobulin and the rate of positivity was 50% (n=72). In
most patients with HLA class I positive tumor cells, the HRS cells
showed a higher staining intensity than the reactive background
cells, especially in EBV+ cases (see figure 2A). For HLA class II
expression by tumor cells, 46% of patients (n=67) were positive.
Usually, the HRS cells were surrounded by HLA class II negative
reactive cells (see figure 2B).
In 26% of patients (n=38) there was co-expression of HLA class
I and class II, whereas in 30% of patients (n=44) the tumor cells
were double negative. Although there was a trend for HLA class I
negative cases to also be HLA class II negative, and vice versa, this
correlation was not statistically significant (Table 2).
Correlation between expression of HLA, EBV status and
clinicopathologic variables
The results of HLA class I and HLA class II expression in
relation to EBV status, the different histological subtypes, sex and
age are summarized in Table 3. Expression of HLA class I was
significantly more frequent in EBV+ than in EBV-neg cases
(P,0.001). Histological subtypes correlated with HLA class I
expression, with the highest frequency of positive expression in the
MC subtype (32/42=76%) and the lowest in the NS subtype
(22/75=29.3%) (P,0.001). Using multivariate logistic regression
analysis a significant effect of EBV status on HLA class I
HLA Expression in Chinese cHL
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(P,0.001). However subtype did not remain significant when
correcting for EBV status implying that EBV status explained the
observed association between histological subtype and HLA class I
expression. In contrast, HLA class II expression was not associated
with EBV or subtype. Neither HLA class I nor HLA class II
expression was found to correlate with patients’ age. In addition,
our data showed that Chinese female cHL patients more
frequently maintained expression of HLA class II (P=0.01), but
not expression of HLA class I.
Comparison between Chinese and Dutch cHL patients
The data from the current Chinese population were compared
with data from a population based study in the Netherlands,
performed by our group [12]. EBV positivity and MC subtype
were more common in Chinese cHL patients than in Dutch cHL
patients (40% vs. 33% and 29% vs. 11%, respectively). In the
Chinese cHL patients, the proportion of children was higher
(age,18: 22.8% vs. 9.2%) while that of the elderly was lower
(age.60: 9.0% vs. 15.8%). A similar association of HLA class I
expression with EBV status was observed in both populations.
However, expression of HLA class II highly correlated with HLA
class I in the Dutch population, which was not the case in Chinese
patients. Loss of HLA class II expression by HRS cells was more
common in Chinese compared to Dutch patients (54% vs. 41%).
This difference was independent of sex, EBV status and
histological subtype, shown using a multivariate logistic regression
model (P=0.012). Table 4 shows that in Dutch patients the
expression of HLA class II was strongly associated with EBV
positivity (P=0.005). Also, the NS subtype was more frequently
deficient in HLA class II expression than the MC subtype
(P=0.016). Neither of these associations was observed in the
Chinese cHL patients. However, only in the Chinese cHL patients
an association between sex and HLA class II expression was
observed (P=0.01).
Discussion
This study involved the largest group of northern Chinese cHL
patients evaluated for expression of HLA class I and HLA class II
by HRS cells. HLA class I expression was strongly associated with
Table 1. Distribution of age, sex and histology by EBV status.
All patients
n=145
EBV-Positive
n=58
EBV-Negative
n=87 P
median age
(range)
28(4–74) 31 (4–74) 28 (8–74) 0.56
{
Sex
Male 66.2% (n=96) 79.3% (n=46) 57.5% (n=50) 0.006*
Female 33.7% (n=49) 20.7% (n=12) 42.5% (n=37)
Histological
subtype
NS 51.7% (n=75) 20.7% (n=12) 72.4% (n=63) ,0.001
{
MC 29.0% (n=42) 51.7% (n=30) 13.8% (n=12)
LR 1.4% (n=2) 3.4% (n=2) 0% (n=0)
NOS 17.9% (n=26) 24.2% (n=14) 13.8% (n=12)
{Mann Whitney U test.
*Chi square test.
{Fisher’s exact test.
NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; NOS,
not otherwise specified.
doi:10.1371/journal.pone.0010865.t001
Figure 2. Immunohistochemical detection of Human Leukocyte
Antigen (HLA) expression on formalin-fixed paraffin-
embedded tissue sections of classical Hodgkin lymphoma
(cHL). (A) HLA class I (using the HC-10 antibody) expression in cHL. All
cells show immunoreactivity on the membrane. Hodgkin and Reed–
Sternberg (HRS) cells stand out with their stronger signal (arrow)
(original magnification 406). (B) HLA class II (CR3/43) expression in cHL.
Most HRS cells are positive (arrow), surrounded by negative inflamma-
tory cells (original magnification 640).
doi:10.1371/journal.pone.0010865.g002
Figure 1. In situ hybridization (ISH) for EBERs in an EBV+ cHL
case. The EBER-ISH revealed a homogeneous positive signal in the
nucleus of all Hodgkin and Reed–Sternberg (HRS) cells as well as in
some small reactive cells (original magnification 640).
doi:10.1371/journal.pone.0010865.g001
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association between HLA class II expression and EBV status was
not apparent, in contrast to the data from Western Europe.
The EBV association with cHL has been investigated by several
research groups within different geographic locales and ethnicities,
showing a common association between EBV-associated cHL,
male sex and MC subtype [3,5]. These associations were also
present in this northern Chinese patient population.
Although the pathogenesis of cHL is still not clearly
established, immune escape mechanisms seem to play an
important role, especially in cases that are EBV-associated.
Downregulation of HLA on the surface of tumor cells has been
observed in various types of human malignancies, including cHL
[18]. Our present data demonstrate that deficiency in membra-
nous expression of HLA antigen by tumor cells is quite common
in EBV-neg cHL, since 49.7% and 46.2% cases expressed HLA
class I or class II respectively and only 26.2% cases expressed
both. Lack of HLA expression is generally thought to be
advantageous for the persistence of tumor cells by escaping T
cell mediated immunosurveillance.
An intriguing finding is that HLA class I expression is usually
retained in EBV+ cases, although HLA class I-restricted CTL
responses in general play a major role in eliminating virus
infection. This correlation is consistent with the results of four
previous studies performed on Caucasian cHL populations from
the Netherlands and the United Kingdom [13,14,16]. Our data
also show a correlation between HLA class I expression and MC
subtype, which can be attributed to the close relationship of EBV
involvement with MC subtype. It is apparent that not only the
quantity, but also the quality of HLA molecules determines the
ability to mount an immune response. The composition of HLA
alleles determines the peptide-binding ability and the subsequent
immune response. A recent report on a detailed investigation
within the HLA region lends proof to this concept, as patients with
EBV-associated cHL more frequently carry HLA-A*01 in
comparison to EBV-negative cHL patients who usually carry
HLA-A*02 instead [11,15]. It should be noted that persistence of
HLA class I expression can be advantageous for the tumor cells to
survive Natural Killer cell-mediated lysis [19].
HLA class II-restricted CD4 T cell immune responses are
largely, but not exclusively restricted to exogenous antigens and it
has become evident that these responses are essential for an
efficient eradication of EBV infection [10]. Our group previously
reported a significant association of HLA class II expression with
EBV status in 292 Dutch cHL patients. In contrast, we did not
find this association in the Chinese population in the current study,
although we could see a slight non-significant tendency to
maintain the expression of HLA class II in EBV-associated cHL.
In addition, the previously reported correlation between the
expression of HLA class I and class II [12] was absent in the present
study. A major difference between the Dutch and Chinese
population is the percentage of MC subtype patients with 10.6%
and 28.9% of patients respectively. Strikingly, the expression of
HLA class II in MC subtype patients was very different between the
two populations and was much more frequently downregulated in
the Chinese patients. Since we used the same antibody, staining
protocols and scoring criteria for evaluating HLA class II expression
in both populations, the differential expression likely reflects a
Table 2. Correlation between HLA class I and class II
expression.
HLA class I P{
Positive
n=72
Negative
n=73
HLA class II
Positive (n=67) 52.3% (n=38) 39.7% (n=29) 0.115
Negative (n=78) 47.7% (n=34) 60.3% (n=44)
{Chi square test.
doi:10.1371/journal.pone.0010865.t002
Table 3. HLA class I and class II expression by HRS cells in relation to EBV status, histology, sex and median age.
HLA class I P
{ HLA class II P
{
Positive
n=72
Negative
n=73
Positive
n=67
Negative
n=78
EBV
Pos. 64% (n=46) 16% (n=12) ,0.001 45% (n=30) 36% (n=28) 0.277
Neg. 36% (n=26) 84% (n=61) 55% (n=37) 64% (n=50)
Histology
NS 31% (n=22) 72% (n=53) ,0.001
* 51% (n=34) 53% (n=41) 0.955
*
MC 44% (n=32) 14% (n=10) 27% (n=18) 31% (n=24)
LR 3% (n=2) 0% (n=0) 1% (n=1) 1% (n=1)
NOS 22% (n=16) 14% (n=10) 21% (n=14) 15% (n=12)
Sex
Male 67% (n=48) 66% (n=48) 0.907 55% (n=37) 75% (n=59) 0.01
Female 33% (n=24) 34% (n=25) 45% (n=30) 25% (n=19)
median age (range) 33 (4,74) 26 (6,61) 0.246
{ 28 (4,74) 28 (4,74) 0.666
{
{Chi square test.
*Fisher’s exact test, NOS histology not included.
{Mann Whitney U test.
NS indicates nodular sclerosis; MC, mixed cellularity; LR, lymphocyte rich; NOS, not otherwise specified.
doi:10.1371/journal.pone.0010865.t003
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presumably relates to HLA-based genetic heterogeneity. The HLA
system is extremely polymorphic and allelic frequencies vary
dramatically between racial groups. A certain HLA allele that is
relatively uncommon in one population can be highly prevalent and
associated with a specific disease in another. In the Chinese
population one or more prevalent HLA class II allele(s) might
present immunodominant EBV antigenic peptides to the immune
system, thereby exerting selection pressure to downregulate this
molecule. Thus, yet-to-be-defined ethnic-specific HLA alleles are
likely to affect the strength of association between HLA class II
expression and the strongly EBV associated MC subtype. It should
be noted that Oudejans et al [16] also studied the expression of
HLA class II in Dutch cHL patients, but did not find the same
association. However, they used another antibody, recognizing
HLA-DR only, the sample size of their study was much smaller
(n=63) and they used a different set of scoring criteria [16].
An additional association found in the Chinese population was a
strong correlation between downregulation of HLA class II with
male sex. Since male sex is associated with EBV+ tumor cell status
in general, this might partially explain the lack of association of
HLA class II with EBV status in the Chinese patients. However,
there is no obvious explanation for the association of HLA class II
expression with sex. Interestingly, lack of HLA class II expression
is related to inferior failure free survival in the Dutch population
[12]. An important consequence of the differences in HLA class II
expression between the Chinese and Dutch patients might be that
this adverse prognostic impact of HLA class II absence is not
necessarily present in other populations.
In conclusion, our data demonstrate that in northern Chinese
patients, EBV+ cHL tumor cells more frequently retain HLA class I
expression, similar to Caucasian populations. However, the
association of HLA class II expression with positive EBV status,
as observed in Caucasians, is not present in the northern Chinese
population. Investigation at the molecular level is needed to further
explore the role of anti-tumor immune responses in the pathogen-
esis of cHL. Differences in ethnic background should be taken into
account and might explain discrepancies in incidence pattern, EBV
association and other aspects in different populations.
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